Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Common Equity (2020 - 2025)

Historic Common Equity for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $84.6 million.

  • Barinthus Biotherapeutics' Common Equity fell 4697.07% to $84.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.6 million, marking a year-over-year decrease of 4697.07%. This contributed to the annual value of $130.1 million for FY2024, which is 3040.72% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Common Equity is $84.6 million, which was down 4697.07% from $102.5 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' Common Equity's 5-year high stood at $254.8 million during Q2 2022, with a 5-year trough of -$52.8 million in Q1 2021.
  • Its 5-year average for Common Equity is $181.2 million, with a median of $195.6 million in 2023.
  • Per our database at Business Quant, Barinthus Biotherapeutics' Common Equity skyrocketed by 78422.74% in 2021 and then crashed by 4697.07% in 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Common Equity (Quarter) stood at $252.6 million in 2021, then dropped by 3.71% to $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then tumbled by 30.41% to $130.1 million in 2024, then tumbled by 35.02% to $84.6 million in 2025.
  • Its Common Equity stands at $84.6 million for Q3 2025, versus $102.5 million for Q2 2025 and $115.6 million for Q1 2025.